<DOC>
	<DOC>NCT02540213</DOC>
	<brief_summary>This non-interventional, observational study investigates the efficiency, safety and acceptance of MIRCERA in participants, who received erythropoiesis stimulating agent (ESA) using a self-application system. For each participant, the investigator documents 9 months of treatment with Mircera with respect to efficacy, safety and acceptance.</brief_summary>
	<brief_title>Observational Study of MIRCERA in Users of Self-Application and Multidose Systems</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Anemia caused by CKD only Life expectancy of more than (&gt;) 9 months in the judgment of the attending physician Ferritin &gt;200 micrograms per liter (mcg/L) in accordance with the relevant guidelines The time point of changing to Mircera was only 3 months ago at the longest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>